Form 4: Nevro Corp. CFO Roderick H. MacLeod Reports Stock Disposal

Roderick H. MacLeod, SVP and CFO of Nevro Corp., reported the disposal of 816 shares of common stock on May 28, 2024, to cover tax obligations related to restricted stock units.

Summary

• On May 28, 2024, Roderick H. MacLeod, the SVP and Chief Financial Officer of Nevro Corp., disposed of 816 shares of common stock.
• The transaction was executed at a price of $9.52 per share.
• Following the transaction, MacLeod directly owns 139,888 shares of Nevro Corp., which includes 120,243 restricted stock units.

Sentiment

Score: 5

Explanation: This Form 4 filing is a routine disclosure of a stock transaction by a company insider. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions, which can be closely watched by investors for signals about a company's prospects. The disposal of shares to cover tax obligations is a common occurrence.

Comparison to Industry Standards

• Comparing Roderick H. MacLeod's transactions to those of other CFOs in similarly sized medical device companies would provide context.
• For example, CFOs at companies like Inspire Medical Systems or Axonics Modulation Technologies also regularly file Form 4s related to stock options and restricted stock units.
• Analyzing the frequency and size of these transactions relative to their overall holdings can offer insights into management's sentiment and compensation structures.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on stakeholders, as it is a routine disposal of shares for tax purposes.

Key Dates